Lexicon Pharmaceuticals | LXRX - Przychody Ze Sprzedaży





Obroty Zmiana Data
Abbott USD 11.16B 300M 2026-03
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
Agios Pharmaceuticals USD 18.8M 1.17M 2026-03
Akebia Therapeutics USD 57.62M 1.14M 2025-12
Alnylam Pharmaceuticals USD 1.17B 70M 2026-03
AstraZeneca USD 15.29B 213M 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Coherus Biosciences USD 12.75M 1.18M 2025-12
Eli Lilly USD 19.8B 500M 2026-03
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Halozyme Therapeutics USD 377M 74.76M 2026-03
Illumina USD 1.09B 70M 2026-03
Insmed USD 305.96M 42.16M 2026-03
Ironwood Pharmaceuticals USD 106.51M 58.8M 2026-03
J&J USD 24.1B 500M 2026-03
Lexicon Pharmaceuticals USD 5.49M 8.69M 2025-12
MacroGenics USD 20.8M 20.43M 2026-03
MannKind USD 90.2M 21.76M 2026-03
Merck USD 16.29B 110M 2026-03
Moderna USD 389M 289M 2026-03
Novartis USD 13.11B 226M 2026-03
PTC Therapeutics USD 273M 108.3M 2026-03
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sarepta Therapeutics USD 730.8M 287.9M 2026-03
Thermo Fisher Scientific USD 11.01B 1.2B 2026-03
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
United Therapeutics USD 781.5M 8.7M 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12